ClinicalTrials.gg

Program

masitinib

Also written as “Masitinib”, “masitinib (AB1010)” and “Masitinib (4.5)”.

Its studies are mostly in Multiple Sclerosis, Chronic Progressive · Alzheimer Disease · Amyotrophic Lateral Sclerosis · Asthma · Arthritis, Rheumatoid, led by AB Science.

Furthest: phase 3, since Nov 12, 200838 company-led studies, 4 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AB Science384 open or runningphase 3since Nov 12, 2008Nov 12, 2008Dec 2027phase 3 · NCT03127267

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 23 studies since Nov 12, 2008.

  1. Oct 20, 2015Phase 3 study in Amyotrophic Lateral SclerosisNCT02588677 · 394 enrolled · Spain
  2. Nov 5, 2015Phase 3 study in Colorectal NeoplasmsNCT02605044 · 123 enrolled · France, Singapore, United Kingdom
  3. Apr 13, 2017Phase 3 study in Amyotrophic Lateral SclerosisNCT03127267 · 495 planned · United States, Belgium, Denmark and more
  4. Jun 3, 2018Phase 3 study in Colorectal Cancer MetastaticNCT03556956 · 219 enrolled · Czechia, France, Russian Federation and more
  5. Nov 30, 2018Phase 3 study in Metastatic Castrate Resistant Prostate CancerNCT03761225 · 714 enrolled · Canada, France, India and more
  6. Dec 4, 20182 phase 3 studiesNCT03766295, NCT03771040
  7. Apr 1, 2020Phase 3 study in Mastocytosis, SystemicNCT04333108 · 140 planned · France, Germany, Netherlands and more
  8. Nov 9, 2020Phase 2 study in COVID-19NCT04622865 · 200 enrolled · France
  9. Sep 16, 2021Phase 2 study in COVID-19NCT05047783 · 78 enrolled · France, Russian Federation, South Africa
  10. Dec 27, 2021Early phase 1 study in Healthy VolunteersNCT05200169 · 4 enrolled · United Kingdom
  11. Jun 28, 2022Phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT05441488 · 800 enrolled · France, Greece, Italy and more
  12. Jul 2, 2022Phase 2 study in Mast Cell Activation SyndromeNCT05449444 · 72 enrolled · United States, France
  13. Sep 29, 2022Phase 3 study in Alzheimer DiseaseNCT05564169 · 600 planned · France, Spain
  14. Sep 11, 2025Phase 3 study in Amyotrophic Lateral SclerosisNCT07174492 · 412 planned · Greece

Ahead

  1. Dec 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisNCT03127267
  2. Dec 2028Primary completion: phase 3 study in Alzheimer DiseaseNCT05564169
  3. Dec 31, 2028Primary completion: phase 3 study in Amyotrophic Lateral SclerosisNCT07174492

TargetBeta

“Fibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor”ChEMBL 37, by rule

Studies

All 38 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07174492Amyotrophic Lateral Sclerosis · Greece3Not yet recruitingDec 31, 2028412
NCT05564169Alzheimer Disease · France, Spain3Not yet recruitingDec 2028600
NCT05449444Mast Cell Activation Syndrome · United States, France2UNKNOWNDec 31, 202472
NCT05441488Multiple Sclerosis, Chronic Progressive · France, Greece, Italy and more3SuspendedDec 2028800
NCT05200169Healthy Volunteers · United KingdomEarly 1CompletedSep 1, 20174
NCT05047783COVID-19 · France, Russian Federation, South Africa2UNKNOWNDec 202378
NCT04622865COVID-19 · France2UNKNOWNDec 2023200
NCT04333108Mastocytosis, Systemic · France, Germany, Netherlands and more3RecruitingDec 2024140
NCT03771040Asthma · Argentina, Malaysia, Peru and more3CompletedSep 2020347
NCT03766295Pancreatic Neoplasms · Belgium, France, Greece and more3CompletedDec 2020377
NCT03761225Metastatic Castrate Resistant Prostate Cancer · Canada, France, India and more3CompletedDec 15, 2020714
NCT03556956Colorectal Cancer Metastatic · Czechia, France, Russian Federation and more3CompletedDec 2020219
NCT03127267Amyotrophic Lateral Sclerosis · United States, Belgium, Denmark and more3RecruitingDec 2027495
NCT02605044Colorectal Neoplasms · France, Singapore, United Kingdom3TerminatedDec 2017123
NCT02588677Amyotrophic Lateral Sclerosis · Spain3CompletedDec 5, 2016394
NCT02490488Ovarian Neoplasms · Algeria, France, Russian Federation and more3CompletedDec 2020248
NCT02009423Gastro-Intestinal Stromal Tumour3TerminatedNov 20157
NCT01872598Alzheimer Disease · Bulgaria, Greece, Poland and more3CompletedDec 2020721
NCT01694277Gastrointestinal Stromal Tumors · United States, France, Italy and more3CompletedDec 2020258
NCT01506336Gastro Intestinal Stromal Tumor · France2CompletedSep 201144
NCT01470131Multiple Myeloma · United States, France3TerminatedJan 4, 2017147
NCT01450488Multiple Sclerosis2CompletedJul 200735
NCT01449162Asthma · Bulgaria, Czechia, France and more3CompletedNov 2019420
NCT01433497Multiple Sclerosis, Chronic Progressive · Bulgaria, France, Germany and more3CompletedSep 2019656
NCT01410695Arthritis, Rheumatoid · Czechia3TerminatedOct 2015324
NCT01266369Mastocytosis2CompletedNov 200721
NCT01280565Melanoma · United States, Czechia, France and more3TerminatedAug 2019134
NCT01045577Psoriasis2CompletedJan 200625
NCT00998751Gastro-intestinal Stromal Tumours · France2CompletedJun 201330
NCT00976118Alzheimer Disease2CompletedJul 200834
NCT00913432Arthritis, Rheumatoid2CompletedJun 200920
NCT00866138Multiple Myeloma · France2CompletedJan 201124
NCT00842270Asthma2CompletedJul 200744
NCT00831974Mastocytosis2CompletedFeb 200723
NCT00831922Arthritis, Rheumatoid2CompletedOct 200643
NCT00814073Mastocytosis, Systemic · United States, France3CompletedNov 2015135
NCT00812240Gastrointestinal Stromal Tumors · United States, France, Lebanon3TerminatedJul 2018335
NCT00789633Pancreatic Neoplasms · United States, Czechia, France and more3CompletedDec 23, 2011353

How it is read

Names in the registry

  • “Masitinib”, 19 entries
  • “masitinib (AB1010)”, 6 entries
  • “masitinib”, 6 entries
  • “Masitinib (4.5)”, 4 entries
  • “AB1010”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.